Immuneering Corp
Immuneering Corporation (Nasdaq: IMRX) is a late-stage clinical oncology company focused on developing and commercializing an entirely new category of anti-cancer medicines called Deep Cyclic Inhibitors. The company's website is www.immuneering.com. From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Immuneering Corp does
In the company’s own words
Immuneering Corporation (Nasdaq: IMRX) is a late-stage clinical oncology company focused on developing and commercializing an entirely new category of anti-cancer medicines called Deep Cyclic Inhibitors. The company's website is www.immuneering.com.
Founded in 2008, Immuneering leverages translational bioinformatics and proprietary 3D tumor modeling to discover and develop novel small molecule drug programs. The company's platform analyzes high-throughput molecular-level biochemical assays, including transcriptomics, genomics, and proteomics data, combined with in vitro studies using humanized 3D tumor growth assays designed to predict in vivo activity more accurately than traditional cell culture models.
The company's lead product candidate is atebimetinib (IMM-1-104), an oral, once-daily Deep Cyclic Inhibitor of mitogen-activated protein kinase kinase (MEK) designed to improve durability and tolerability across multiple cancer indications, particularly MAPK pathway-driven tumors such as pancreatic cancer. Atebimetinib is currently in Phase 1/2a clinical trials and is expected to enter a Phase 3 registrational trial (MAPKeeper 301) in mid-2026 evaluating the drug in combination with modified gemcitabine/nab-paclitaxel in first-line pancreatic cancer patients. The FDA has granted Fast Track designation for atebimetinib in multiple indications and orphan drug designation for pancreatic cancer treatment.
Immuneering's pipeline also includes envometinib (IMM-6-415), an allosteric MEK inhibitor in Phase 1/2a development, and additional early-stage discovery programs targeting core cancer signaling pathways outside the MAPK pathway. The company's differentiated approach aims to cyclically disrupt abnormal pathway activation while sparing healthy cells, contrasting with traditional targeted therapies that chronically suppress pathways and often result in toxicity and adaptive resistance.
The company has established clinical supply agreements with Regeneron Pharmaceuticals for Libtayo (cemiplimab) and with Eli Lilly for olomorasib to support combination therapy trials in lung cancer patients. Immuneering's multidisciplinary research and development team brings expertise from leading pharmaceutical and biotechnology companies including Johnson & Johnson, Merck, Regeneron, AstraZeneca, and Novartis.
Company details
- Sector
- Healthcare
- Industry
- Pharmaceutical Preparations
- Headquarters
- CAMBRIDGE, MA
- Fiscal year end
- December
- CIK
- 1790340
- SIC
- 2834
Financial performance, year by year
Fiscal 2021–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Immuneering Corp — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Immuneering Corp’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Could not be determined for this company: bond issues.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Immuneering Corp and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Immuneering Corp's earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Immuneering Corp's last four quarterly filings that the numbers alone won't show?”